HEMO vs. SBTX, COS, C4XD, DDDD, POLB, OKYO, SAR, SNG, AOR, and AREC
Should you be buying Hemogenyx Pharmaceuticals stock or one of its competitors? The main competitors of Hemogenyx Pharmaceuticals include SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Poolbeg Pharma (POLB), OKYO Pharma (OKYO), Sareum (SAR), Synairgen (SNG), AorTech International (AOR), and Arecor Therapeutics (AREC). These companies are all part of the "biotechnology" industry.
Hemogenyx Pharmaceuticals vs.
SkinBioTherapeutics (LON:SBTX) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership, community ranking and analyst recommendations.
In the previous week, SkinBioTherapeutics' average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.
Hemogenyx Pharmaceuticals received 8 more outperform votes than SkinBioTherapeutics when rated by MarketBeat users. However, 60.26% of users gave SkinBioTherapeutics an outperform vote while only 57.89% of users gave Hemogenyx Pharmaceuticals an outperform vote.
Hemogenyx Pharmaceuticals has lower revenue, but higher earnings than SkinBioTherapeutics. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than SkinBioTherapeutics, indicating that it is currently the more affordable of the two stocks.
Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -237.95%. Hemogenyx Pharmaceuticals' return on equity of -80.66% beat SkinBioTherapeutics' return on equity.
SkinBioTherapeutics has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500. Comparatively, Hemogenyx Pharmaceuticals has a beta of 3.14, suggesting that its share price is 214% more volatile than the S&P 500.
16.6% of SkinBioTherapeutics shares are owned by institutional investors. Comparatively, 0.8% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 20.4% of SkinBioTherapeutics shares are owned by insiders. Comparatively, 10.7% of Hemogenyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Hemogenyx Pharmaceuticals beats SkinBioTherapeutics on 7 of the 12 factors compared between the two stocks.
Get Hemogenyx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hemogenyx Pharmaceuticals Competitors List
Related Companies and Tools
This page (LON:HEMO) was last updated on 2/22/2025 by MarketBeat.com Staff
